Version 1
: Received: 25 February 2023 / Approved: 6 March 2023 / Online: 6 March 2023 (02:38:13 CET)
How to cite:
Liu, H.; Tang, T. CENPA Was a Cell Cycle Biomarker in Cancers With Diagnostic Prognostic, and Therapeutic Value. Preprints2023, 2023030082. https://doi.org/10.20944/preprints202303.0082.v1
Liu, H.; Tang, T. CENPA Was a Cell Cycle Biomarker in Cancers With Diagnostic Prognostic, and Therapeutic Value. Preprints 2023, 2023030082. https://doi.org/10.20944/preprints202303.0082.v1
Liu, H.; Tang, T. CENPA Was a Cell Cycle Biomarker in Cancers With Diagnostic Prognostic, and Therapeutic Value. Preprints2023, 2023030082. https://doi.org/10.20944/preprints202303.0082.v1
APA Style
Liu, H., & Tang, T. (2023). CENPA Was a Cell Cycle Biomarker in Cancers With Diagnostic Prognostic, and Therapeutic Value. Preprints. https://doi.org/10.20944/preprints202303.0082.v1
Chicago/Turabian Style
Liu, H. and Tao Tang. 2023 "CENPA Was a Cell Cycle Biomarker in Cancers With Diagnostic Prognostic, and Therapeutic Value" Preprints. https://doi.org/10.20944/preprints202303.0082.v1
Abstract
Background Cancer is one of the most concerning public health issues in the world. One of cancer hallmarks wildly accepted is sustaining proliferative signaling, which involved most of the cell cycle biological activities. Centromeric histone, Centromere Protein A (CENPA), a variant of canonical histone H3, plays an essential role in selective chromosome segregation in the cell cycle. However, so far, a systematic pan-cancer bioinformatic analysis has not been done yet. Methods We accessed genome, transcriptome, and clinical information from open databases. The genetic alteration, mRNA expression, functional enrichment, stemness, mutation association, expression in cell populations and cellular locations, cell cycle association, survival association of CENPA, and immune association were analyzed. A prognostic model for glioma patients was constructed as an example application of CENPA as a biomarker. Drugs targeting CENPA in cancer cells were also screened and predicted by the CENPA correlation of drug sensitivity and protein-ligand docking. Results CENPA had low gene mutation in cancers. CENPA was overexpressed in almost all cancer types in TCGA compared to their normal control. CENPA was highly expressed in the nucleus of malignant cells. CENPA was associated with the cell cycle of cancer cells. CENPA is a biomarker for the cell cycle G2 phase in cancer cells. CENPA was a diagnostic and prognostic biomarker across multiple cancer types. The prognosis of glioma with CENPA was reliable and can be applied with other prognostic factors. CENPA was associated with the immune microenvironment. Drugs CD-437, 3-Cl-AHPC, Trametinib, BI-2536, and GSK461364 were predicted to target CENPA in cancer cells. Conclusion CENPA was a cell cycle biomarker in cancers with diagnostic and prognostic value.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
